Clinical trials
Pregnancy, High Risk clinical trials
Below are recruiting pregnancy, high risk clinical trials, each written for real people, not researchers. We’re tracking 361 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06013618RecruitingPhase 2
Naxitamab for high-risk or relapsed neuroblastoma in children
This trial tests a targeted antibody called naxitamab (hu3F8) for children with high-risk neuroblastoma that has come back or is hard to treat. It aims to see if this therapy can help shrink or control the cancer with an acceptable safety profile.
Guangzhou, GuangdongAges 1 year+ - NCT06037980RecruitingPhase 2/Phase 3
Chemotherapy before surgery for high-risk bile duct cancer
This trial tests whether receiving chemotherapy (cisplatin, gemcitabine, and nab-paclitaxel) before surgery can improve outcomes for people with high-risk bile duct or gallbladder cancer. It compares this approach to going straight to surgery.
AnconaAges 18–75 - NCT06071897RecruitingPhase 3
Chemo-immunotherapy for high-risk neuroblastoma
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
MoscowAges 1.5 years–18 years - NCT06092957RecruitingPhase 3
Reduced radiation after chemo-immunotherapy for high-risk nasopharyngeal cancer
This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.
Guangzhou, GuangdongAges 18–70 - NCT06093061RecruitingPhase 2
Maintenance therapy for high-risk nasopharyngeal cancer
This trial tests a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and capecitabine (a chemo pill taken daily)—as maintenance therapy after initial chemotherapy for high-risk nasopharyngeal cancer. The goal is to see if this approach can lower the chance of cancer coming back.
SingaporeAges 21–99 - NCT06096805Recruiting
Predicting fetal growth restriction in high-risk pregnancies
This study aims to better predict fetal growth restriction (when a baby doesn't grow as expected) in women who have certain risk factors. By joining, you may help doctors develop better screening tools for future pregnancies.
Shanghai, Shanghai MunicipalityAges 18–45 - NCT06100237RecruitingPhase 2
Teclistamab and daratumumab for high-risk smoldering myeloma
This trial tests two immunotherapy drugs (teclistamab and daratumumab) for people with high-risk smoldering myeloma to see if the combination can stop or delay progression to active multiple myeloma. It's a new approach for those whose smoldering myeloma has a higher chance of becoming active.
Miami, FloridaAges 18 years+ - NCT06104592RecruitingPhase 2
Radiation before CAR T-cell therapy for high-risk large B-cell lymphoma
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
Tampa, FloridaAges 18 years+ - NCT06111079RecruitingPhase 3
Stopping Aspirin in High-Risk Pregnant Women
This trial tests whether stopping aspirin use in high-risk pregnant women can be safe. It aims to find the best time to stop taking aspirin to prevent preeclampsia, a condition that causes high blood pressure during pregnancy.
Guangzhou, GuangdongAges 18–45 - NCT06143969Recruiting
Ultrasound-guided clot-dissolving treatment for intermediate-high risk pulmonary embolism
This trial tests a treatment that uses ultrasound to guide a thin tube (catheter) to deliver clot-busting medicine directly into the blood clot in your lung. It may be an option for people whose clot is serious but not yet causing shock, and who have symptoms that started within the last two weeks.
Milan, ItaliaAges 18 years+ - NCT06170710RecruitingPhase 2
Immunotherapy after chemoradiation for high-risk head and neck cancer
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
Beijing, Beijing MunicipalityAges 18–70 - NCT06183489RecruitingPhase 2
Elranatamab for high-risk smoldering multiple myeloma
This trial tests a new drug called Elranatamab for people with a high-risk form of smoldering multiple myeloma (SMM). The goal is to see if the drug can prevent or delay the progression to active multiple myeloma.
HelsinkiAges 18 years+ - NCT06207799RecruitingPhase 2
Drug combo before and after transplant for high-risk myeloma
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
Houston, TexasAges 18–75 - NCT06228599Recruiting
Targeted therapy for pancreatic cancer with high risk of return
This trial tests if personalized medicines, chosen based on the genetic profile of your tumor, can help prevent pancreatic cancer from coming back after surgery. It is for people who have had their pancreatic tumor removed but have features that suggest a higher chance of recurrence.
Milwaukee, WisconsinAges 18 years+ - NCT06240143RecruitingPhase 1/Phase 2
Intradermal immunotherapy for high-risk stage II melanoma
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
AmsterdamAges 18 years+ - NCT06319196RecruitingPhase 2
Clearing melanoma with immunotherapy after surgery
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
Toronto, OntarioAges 18 years+ - NCT06558604RecruitingPhase 2
Study of glofitamab with venetoclax for high-risk mantle cell lymphoma
This trial tests a new combination of drugs (glofitamab plus venetoclax, with or without zanubrutinib) for people with mantle cell lymphoma that is either newly diagnosed with high risk features, or has come back or not responded to earlier treatments. The goal is to see if these targeted therapies can improve outcomes.
BrugesAges 18–79 - NCT06362746RecruitingPhase 3
Staphylokinase for intermediate high-risk pulmonary embolism
This trial tests a new drug, staphylokinase, to see if it can break up blood clots in the lungs in people with a moderate-high risk pulmonary embolism. The goal is to improve blood flow and reduce the chance of complications.
Barnaul, Altayskiy KrayAges 18 years+ - NCT06407947RecruitingEarly Phase 1
CT071 for high-risk newly diagnosed multiple myeloma
This trial tests an experimental therapy called CT071 for people with newly diagnosed, high-risk multiple myeloma. It aims to see if this treatment can help control the disease in people who have certain aggressive features.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06410690Recruiting
AI tool to predict high-risk coronary plaques from heart scans
This trial uses an artificial intelligence (AI) tool to analyze heart CT scans (CCTA) and identify dangerous plaque buildup that could lead to a heart attack. It aims to see if AI can better predict high-risk plaques in people with known or suspected coronary artery disease (CAD).
Milan, MilanAges 18 years+ - NCT06440850RecruitingPhase 2
Targeted therapy for high-risk BRAF-mutated thyroid cancer
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
Duarte, CaliforniaAges 18 years+ - NCT06455124RecruitingPhase 2
Short radiation and chemo-immunotherapy for early rectal cancer after local surgery
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
ShanghaiAges 18–75 - NCT06482684RecruitingPhase 2
CAR-T cell therapy for new, high-risk mantle cell lymphoma
This study tests a type of immunotherapy called CAR-T cells (modified immune cells) for people with untreated, high-risk mantle cell lymphoma. It aims to see if this therapy can help control the disease early on.
MainzAges 18–75 - NCT06533384RecruitingPhase 3
PARP inhibitor or chemo plus immunotherapy after surgery for high-risk TNBC
This trial tests whether adding a PARP inhibitor or capecitabine (chemo) to a PD-1 inhibitor (immunotherapy) after surgery helps prevent triple-negative breast cancer from coming back. It's for people with high-risk disease who have completed initial treatment.
Guangzhou, GuangdongAges 18–70
Hear when a new Pregnancy, High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pregnancy, high risk?
- Yes. Clin2 currently lists 361 recruiting pregnancy, high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pregnancy, high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pregnancy, high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.